Belmont Capital, LLC Eli Lilly & CO Transaction History

Belmont Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$525.19 - $619.13 $1.41 Million - $1.66 Million	-2,688 Reduced 99.63%	10 $5,000
Q3 2023 Nov 13, 2023	BUY	$434.7 - $599.3 $1.15 Million - $1.59 Million	2,655 Added 6174.42%	2,698 $1.45 Million
Q2 2023 Aug 10, 2023	SELL	$350.74 - $468.98 $3,156 - $4,220	-9 Reduced 17.31%	43 $20,000
Q3 2022 Oct 18, 2022	BUY	$296.48 - $337.87 $12,452 - $14,190	42 Added 420.0%	52 $17,000
Q4 2021 Jan 19, 2022	BUY	$224.85 - $279.04 $2,248 - $2,790	10 New	10 $3,000

4,011

751M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $755B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Belmont Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Belmont Capital, LLC with notifications on news.